These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 2447498

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ, Charache S, Boyer SH.
    Trans Assoc Am Physicians; 1984; 97():140-5. PubMed ID: 6085527
    [No Abstract] [Full Text] [Related]

  • 4. The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease.
    Dover GJ, Charache S.
    Prog Clin Biol Res; 1987; 240():277-85. PubMed ID: 2441416
    [No Abstract] [Full Text] [Related]

  • 5. Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia.
    Dover GJ, Charache S.
    Prog Clin Biol Res; 1989; 316B():295-306. PubMed ID: 2482499
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Jan 14; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
    Coleman E, Inusa B.
    Clin Pediatr (Phila); 2007 Jun 14; 46(5):386-91. PubMed ID: 17556734
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H, Sutton M, Atweh GF.
    Ann N Y Acad Sci; 2005 Jun 14; 1054():228-37. PubMed ID: 16339670
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP.
    Semin Oncol; 1992 Jun 14; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea in sickle cell disease.
    Schechter AN, Rodgers GP.
    N Engl J Med; 1996 Feb 01; 334(5):333. PubMed ID: 8532042
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.
    Am J Hematol; 2003 Feb 01; 72(2):121-6. PubMed ID: 12555216
    [Abstract] [Full Text] [Related]

  • 18. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N, Fattori A, Saad ST, Costa FF.
    Am J Hematol; 2004 Aug 01; 76(4):343-7. PubMed ID: 15282666
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.